Tigecycline use in serious nosocomial infections: a drug use evaluation.
Tigecycline use in serious nosocomial infections: a drug use evaluation.
复制标题
DOI：
10.1186/1471-2334-10-287
复制
发表时间：
2010-09-29
影响因子：
3.7
通讯作者：
Viscoli C
中科院分区：
文献类型：
--
作者：
Bassetti M;Nicolini L;Repetto E;Righi E;Del Bono V;Viscoli C
替加环素是一种新型抗生素，具有对抗多重耐药细菌的活性。本研究的目的是评估替加环素使用对严重医院获得性感染 (HAI) 的疗效。替加环素使用的前瞻性观察研究是在一所拥有 1500 个床位的大学医院中进行的。自2007年1月1日至2010年1月31日，207名患者接受了替加环素治疗，治疗的适应症如下：腹腔内、肺炎、血液及复杂的皮肤软组织感染和发热性中性粒细胞减少症。该治疗针对 130/207 (63%) 患者，针对 77/207 (37%) 患者进行经验治疗。所有处理的细菌都对替加环素敏感。替加环素治疗的中位持续时间为 13 天（范围，6-28 天）。临床成功率为 151/207 (73%)，其中腹腔感染成功率最高 [81/99 (82%)]。 100/129 (78%) 的治疗患者取得了微生物学成功。 16/207 名患者（7.7%）出现不良临床事件：考虑到缺乏替加环素用于危重患者的数据，我们认为我们的临床经验报告数据尽管存在一些局限性，但对临床医生来说可能是有用的。
Tigecycline is a novel antibiotic with activity against multidrug resistant bacteria. The aim of this study was to assess the efficacy of tigecycline use in serious hospital-acquired infections (HAI) Prospective observational study of tigecycline use was conducted in a 1500 beds university hospital. From January 1, 2007 and January 31, 2010, 207 pts were treated with tigecycline for the following indications: intra-abdominal, pneumonia, bloodstream and complicated skin and soft tissue infections and febrile neutropenia. The therapy was targeted in 130/207 (63%) and empirical in 77/207 (37%) patients. All bacteria treated were susceptible to tigecycline. Median duration of tigecycline therapy was 13 days (range, 6-28). Clinical success was obtained in 151/207 (73%) cases, with the highest success rate recorded in intra-abdominal infections [81/99 (82%)]. Microbiological success was achieved in 100/129 (78%) treated patients. Adverse clinical events were seen in 16/207 patients (7.7%): Considering the lack of data on tigecycline for critically ill patients, we think that the reported data of our clinical experience despite some limitations can be useful for clinicians.
登录
查看更多内容
影响因子：
28.2
作者：
Poulakou, Garyphallia;Kontopidou, Flora V.;Giamarellou, Helen
通讯作者：
Giamarellou, Helen
影响因子：
5.2
作者：
Swoboda, Stefanie;Ober, Michael;Weigand, Markus A.
通讯作者：
Weigand, Markus A.
影响因子：
--
作者：
Hyle, EP;Lipworth, AD;Lautenbach, E
通讯作者：
Lautenbach, E
影响因子：
4.9
作者：
GARNER, JS;JARVIS, WR;HUGHES, JM
通讯作者：
HUGHES, JM
影响因子：
5.2
作者：
Bratu, S;Tolaney, P;Landman, D
通讯作者：
Landman, D